Czy mamy wreszcie dowody kliniczne na skuteczność interwencji farmakologicznej w zakresie lipoprotein HDL? – komentarz do badania ARBITER 6 HALTS Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2010
Słowa kluczowe:
cholesterol HDL, niacyna, ezetymib, kompleks intima-media (IMT)
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule omówiono znaczenie lipoprotein HDL w rozwoju choroby wieńcowej. Omówiono potencjalne znaczenie interwencji farmakologicznej nakierowanej na skorygowanie niskiego stężenia cholesterolu HDL w świetle wyników uzyskanych w badaniu ARBITER 6 HALTS z zastosowaniem niacyny.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pikto-Pietkiewicz , W. (2010). Czy mamy wreszcie dowody kliniczne na skuteczność interwencji farmakologicznej w zakresie lipoprotein HDL? – komentarz do badania ARBITER 6 HALTS. Medycyna Faktów , 3(4(9), 54-60. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2564
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Wei L., Ebrahim S., Bartlett C. et al.: Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821.
2. Brugts J.J., Yetgin T., Hoeks S.E. et al.: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
3. Gordon T., Castelli W.P., Hjortland M.C. et al.: High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am. J. Med. 1977; 62: 707-14.
4. Assmann G., Schulte H., von Eckardstein A., Huang Y.: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(suppl): S11-20.
5. Sacks F.; for the Expert Group on HDL Cholesterol: The Role of High-Density Lipoprotein ( HDL) Cholesterol in the Prevention and Treatment of Coronary Heart Disease: Expert Group Recommendations. Am. J. Cardiol. 2002; 90: 139-143.
6. Barter P., Gotto A.M., LaRosa J.C. et al.: HDL-cholesterol, very low levels of LDL cholesterol and cardiovascular events. N. Engl. J. Med. 2007; 357: 1301-10.
7. Fruchart J.C., Sacks F., Hermans M.P. et al.; The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. Am. J. Cardiol. 2008; 102(suppl): 1K-34K.
8. Mukamal K.J., Chen C.M., Rao S.R. et al.: Alcohol Consumption and Cardiovascular Mortality Among U.S. Adults, 1987- 2002. Journal of the American College of Cardiology 2010; 55(13): 1328-1335.
9. Rubins H.B., Robins S.J., Collins D. et al.: Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. N. Engl. J. Med. 1999; 341: 410-418.
10. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus [online: 10.1056/nejmoa1001282 nejm.org].
11. Barter P.J., Caulfield M., Eriksson M. et al.: Effects of Torcetrapib in Patients at High Risk for Coronary Events. N. Engl. J. Med. 2007; 357: 2109-22.
12. Singh I.M., Shishehbor M.H., Ansell B.J.: High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298: 786-98 [errata: JAMA 2007; 298: 1516].
13. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 15; 2(8403): 600-4.
14. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
15. Coronary Drug Project Research Group. Clofibrate and niacin coronary heart disease. JAMA 1975; 231: 360-381.
16. Lamon-Fava S., Diffenderfer M.R., Barret P.H. et al.: Extended released niacin alters metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscl. Thromb. Vasc. Biol. 2008; 28: 1672-8.
17. Taylor A.J., Sullenberger L.E., Lee H.J. et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
18. Brown B.G., Zhao X.Q., Chait A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592.
19. Taylor A.J., Villines T.C., Stanek E.J. et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 2009; 361: 2113-22.
20. Crouse J.R. III, Raichlen J.S., Riley W.A. et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344-53.
21. Villines T.C., Stanek E.J., Devine P.J. et al.: The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 – HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J. Am. Coll. Cardiol. 2010; 55: 2721-2726.
22. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
23. Raal F.J., Santos R.D., Blom D.J. et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010 [DOI: 10.1016/S0140-6736(10)60284-X].
24. Nissen S.E., Nicholls S.J., Wolski K. et al.: Effects of a potent and selective PPAR-{:alpha:} agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. JAMA 2007; 297: 1362-1373.
2. Brugts J.J., Yetgin T., Hoeks S.E. et al.: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
3. Gordon T., Castelli W.P., Hjortland M.C. et al.: High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am. J. Med. 1977; 62: 707-14.
4. Assmann G., Schulte H., von Eckardstein A., Huang Y.: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(suppl): S11-20.
5. Sacks F.; for the Expert Group on HDL Cholesterol: The Role of High-Density Lipoprotein ( HDL) Cholesterol in the Prevention and Treatment of Coronary Heart Disease: Expert Group Recommendations. Am. J. Cardiol. 2002; 90: 139-143.
6. Barter P., Gotto A.M., LaRosa J.C. et al.: HDL-cholesterol, very low levels of LDL cholesterol and cardiovascular events. N. Engl. J. Med. 2007; 357: 1301-10.
7. Fruchart J.C., Sacks F., Hermans M.P. et al.; The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. Am. J. Cardiol. 2008; 102(suppl): 1K-34K.
8. Mukamal K.J., Chen C.M., Rao S.R. et al.: Alcohol Consumption and Cardiovascular Mortality Among U.S. Adults, 1987- 2002. Journal of the American College of Cardiology 2010; 55(13): 1328-1335.
9. Rubins H.B., Robins S.J., Collins D. et al.: Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. N. Engl. J. Med. 1999; 341: 410-418.
10. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus [online: 10.1056/nejmoa1001282 nejm.org].
11. Barter P.J., Caulfield M., Eriksson M. et al.: Effects of Torcetrapib in Patients at High Risk for Coronary Events. N. Engl. J. Med. 2007; 357: 2109-22.
12. Singh I.M., Shishehbor M.H., Ansell B.J.: High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298: 786-98 [errata: JAMA 2007; 298: 1516].
13. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 15; 2(8403): 600-4.
14. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
15. Coronary Drug Project Research Group. Clofibrate and niacin coronary heart disease. JAMA 1975; 231: 360-381.
16. Lamon-Fava S., Diffenderfer M.R., Barret P.H. et al.: Extended released niacin alters metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscl. Thromb. Vasc. Biol. 2008; 28: 1672-8.
17. Taylor A.J., Sullenberger L.E., Lee H.J. et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
18. Brown B.G., Zhao X.Q., Chait A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592.
19. Taylor A.J., Villines T.C., Stanek E.J. et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 2009; 361: 2113-22.
20. Crouse J.R. III, Raichlen J.S., Riley W.A. et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344-53.
21. Villines T.C., Stanek E.J., Devine P.J. et al.: The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 – HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J. Am. Coll. Cardiol. 2010; 55: 2721-2726.
22. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
23. Raal F.J., Santos R.D., Blom D.J. et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010 [DOI: 10.1016/S0140-6736(10)60284-X].
24. Nissen S.E., Nicholls S.J., Wolski K. et al.: Effects of a potent and selective PPAR-{:alpha:} agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. JAMA 2007; 297: 1362-1373.